- Home
- BCDA vs PHGE Comparison
BCDA vs PHGE Comparison
Compare BCDA & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- PHGE
- Stock Information
- Founded
- BCDA N/A
- PHGE 2015
- Country
- BCDA United States
- PHGE Israel
- Employees
- BCDA N/A
- PHGE N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- PHGE Health Care
- Exchange
- BCDA Nasdaq
- PHGE Nasdaq
- Market Cap
- BCDA 10.1M
- PHGE 11.0M
- IPO Year
- BCDA N/A
- PHGE N/A
- Fundamental
- Price
- BCDA $2.35
- PHGE $0.43
- Analyst Decision
- BCDA Strong Buy
- PHGE Strong Buy
- Analyst Count
- BCDA 1
- PHGE 1
- Target Price
- BCDA $25.00
- PHGE $15.00
- AVG Volume (30 Days)
- BCDA 238.1K
- PHGE 3.1M
- Earning Date
- BCDA 08-12-2025
- PHGE 08-13-2025
- Dividend Yield
- BCDA N/A
- PHGE N/A
- EPS Growth
- BCDA N/A
- PHGE N/A
- EPS
- BCDA N/A
- PHGE N/A
- Revenue
- BCDA $3,000.00
- PHGE N/A
- Revenue This Year
- BCDA N/A
- PHGE N/A
- Revenue Next Year
- BCDA N/A
- PHGE N/A
- P/E Ratio
- BCDA N/A
- PHGE N/A
- Revenue Growth
- BCDA N/A
- PHGE N/A
- 52 Week Low
- BCDA $1.63
- PHGE $0.34
- 52 Week High
- BCDA $4.66
- PHGE $2.35
- Technical
- Relative Strength Index (RSI)
- BCDA 54.75
- PHGE 48.13
- Support Level
- BCDA $2.22
- PHGE $0.38
- Resistance Level
- BCDA $2.42
- PHGE $0.46
- Average True Range (ATR)
- BCDA 0.13
- PHGE 0.05
- MACD
- BCDA 0.01
- PHGE 0.01
- Stochastic Oscillator
- BCDA 72.97
- PHGE 16.76
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).